NCT05256446: AMG 701 Expanded Access Program

NCT05256446: AMG 701 Expanded Access Program

AMG 701 Expanded Access Program

Expanded access requests for AMG 701 may be considered for adult patients with relapsed and/or refractory multiple myeloma whose disease is in partial response or better after AMG 420 therapy. To request access, use Responsible Party contact information provided in this record.

Sponsor

Amgen

---

ClinicalTrials.gov Identifier: NCT04998747

AMG 701 Expanded Access Program

First Posted: February 25, 2022

Click here for details on ClinicalTrials.gov

---

pavurutamab - anti-BCMA/CD3 BiTE antibody AMG 701

AMG 701

Pavurutamab (Code C147028)

AMG 701

AMG-701

AMG701

Anti-BCMA x Anti-CD3 BiTE AMG 701

Anti-BCMA/CD3 BiTE Antibody AMG 701

BCMA/CD3-directed Bispecific T-cell Engager Antibody AMG 701

Bispecific T-cell Engager Antibody AMG 701

BiTE Antibody AMG 701

Pavurutamab

PAVURUTAMAB

Drug: AMG 701

---